

Trust Board Paper T

To:	Trust Board						
From:	Peter Hollinshead, Interim Director of Financial Strategy						
Date:	24 April 2014						
CQC regulation:							
Title:	2013/14 Year End Financial Position						
Author/Responsible Director: Peter Hollinshead							
Purpose of the Report:							
<p>This paper provides the Trust Board with an update on performance against the Trust's key financial duties namely:</p> <ul style="list-style-type: none"> • Delivery against the planned surplus • Achieving the External Financing Limit (EFL) • Achieving the Capital Resource Limit (CRL) 							
The Report is provided to the Board for:							
<table border="1"> <tr> <td>Decision</td> <td></td> </tr> </table>		Decision		<table border="1"> <tr> <td>Discussion</td> <td>X</td> </tr> </table>		Discussion	X
Decision							
Discussion	X						
<table border="1"> <tr> <td>Assurance</td> <td>X</td> </tr> </table>		Assurance	X	<table border="1"> <tr> <td>Endorsement</td> <td>X</td> </tr> </table>		Endorsement	X
Assurance	X						
Endorsement	X						
Summary / Key Points:							
<ul style="list-style-type: none"> • The Trust has not delivered its planned surplus and has not met its breakeven duty, however, it has delivered the revised year end forecast deficit of £39.8m • The Trust has formally had its EFL target reset by the Department of Health in Month 11 reporting from a negative £1.4m to £20.7m. The year-end position of £20.2m reflects a small under shoot against the target. • The DoH reduced the Trust's CRL by £6m in February to £36.7m. The year-end position is £36.7m which reflects delivery of the revised position 							
Recommendations:							
<p>The Trust Board is recommended to:</p> <ul style="list-style-type: none"> • Note the contents of this report • Confirm the year end position, prior to the audited accounts, of a deficit of £39.8m. • Note the delivery of the EFL • Note the delivery against the CRL 							
Previously considered at another corporate UHL Committee?							

Finance & Performance Committee	
Board Assurance Framework: yes	Performance KPIs year to date: yes
Resource Implications (eg Financial, HR): yes	
Assurance Implications: yes	
Patient and Public Involvement (PPI) Implications: N/A	
Stakeholder Engagement Implications: yes	
Equality Impact: N/A	
Information exempt from Disclosure: No	
Requirement for further review? Monthly update	

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

REPORT TO: TRUST BOARD

DATE: 24 APRIL 2014

REPORT FROM: PETER HOLLINSHEAD – INTERIM DIRECTOR OF FINANCIAL STRATEGY

SUBJECT: 2013/14 DRAFT YEAR END FINANCIAL POSITION

1. INTRODUCTION AND CONTEXT

1.1. This paper provides the Trust Board with an update on performance against the Trust's key financial duties namely:

- Delivery against the planned surplus
- Achieving the External Financing Limit (EFL)
- Achieving the Capital Resource Limit (CRL)

2. KEY FINANCIAL DUTIES

2.1. The following table summarises the year to date position and full year forecast against the financial duties of the Trust:

Financial Duty	Forecast Plan £'Ms	Forecast Actual £'Ms	RAG
Delivering the Planned Surplus	3.7	(39.8)	R
Achieving the EFL	20.7	20.2	G
Achieving the Capital Resource Limit	36.7	36.7	G

As well as the key financial duties, a subsidiary duty is to ensure suppliers invoices are paid within 30 days – the Better Payment Practice Code (BPPC). The year to date performance is shown in the table below:

Better Payment Practice Code	April - March 14	
	Number	Value £000s
Total bills paid in the year	133,018	559,312
Total bills paid within target	61,699	404,977
Percentage of bills paid within target	46.4	72.4

Key issues:

- The Trust has not delivered its planned surplus and has not met its breakeven duty, however, it has delivered the revised year end forecast deficit of £39.8m. As such the Trust is expected to receive an adverse value for money opinion on its accounts.
- The Trust has formally had its EFL target reset by the Department of Health in Month 11 reporting from a negative £1.4m to £20.7m. The year end position of £20.2m reflects a small under shoot against the target.

- The DoH reduced the Trust's CRL by £6m in February to £36.7m. The year-end position is £36.7m which reflects delivery of the revised position.
- The BPPC performance reflects the impact of the financial deficit of the Trust and the requirement to carefully manage the cash flow.

3. 2014/15 YEAR END FINANCIAL POSITION

3.1. The Month 12 results and year to date performance may be summarised as follows:

	March 2014			April - March 2014		
	Plan £m	Actual £m	Var (Adv) / Fav £m	Plan £m	Actual £m	Var (Adv) / Fav £m
Income						
Patient income	53.9	58.5	4.6	634.2	659.1	24.9
Teaching, R&D	6.0	5.0	(1.0)	73.6	70.2	(3.4)
Other operating Income	3.1	5.6	2.5	38.2	40.7	2.5
Total Income	63.1	69.1	6.0	746.0	770.0	24.0
Operating expenditure						
Pay	37.1	41.1	(4.0)	447.6	474.2	(26.6)
Non-pay	23.0	26.6	(3.6)	274.7	294.0	(19.3)
Reserves	(2.1)	-	(2.1)	(24.1)	-	(24.1)
Total Operating Expenditure	58.1	67.7	(9.7)	698.2	768.2	(69.9)
EBITDA	5.0	1.4	(3.6)	47.7	1.8	(45.9)
Net interest	-	-	-	0.0	0.0	0.0
Depreciation	(2.7)	(2.4)	0.3	(32.5)	(31.0)	1.5
PDC dividend payable	(1.0)	(0.4)	0.6	(11.6)	(10.7)	0.9
Net deficit	1.3	(1.4)	(2.7)	3.7	(39.8)	(43.5)
EBITDA %		2.0%			0.2%	

3.2. The Trust is reporting, prior to the audited accounts, the following year end position:

- A deficit at the end of the financial year of £39.8m, which is adverse to the plan by £43.5m
- In month position is a £1.4m deficit, £2.7m adverse to the Plan

3.3. The significant reasons for the year to date variances against income and operating expenditure are:

Patient Care Income

- Patient care income is significantly over-performing against the Plan (3.9%). The details by point of delivery and the price/volume impact are shown in Appendix 2 for NHS patient care income.
- The key factors to highlight from the Appendix are:
 - £9.8m of additional income YTD from the winter funding allocation
 - £9.6m over-performance in the other category. This includes critical care, excluded drugs and devices, and direct access
 - £2.5m over-performance in inpatient activity (day case and elective)
 - £4.7m over-performance in Outpatients reflecting the success of the Outpatient Transformation Programme and also an increasing number of referrals

- The Trust is reporting £6.2m reduction of income, £3.4m adverse to Plan against the marginal rate emergency threshold (30% of tariff received)
- The price/volume analysis clearly shows the significant increase in volume of activity across the points of delivery which in turn have an impact on our cost base


Pay

- Pay expenditure is £26.6m above budget YTD, 5.9%. The significant factors for this are:
 - Additional costs to support the patient care activity
 - Investment of staffing from the winter funding
 - Under delivery against the CIP programme
 - Additional staff, particularly in the Emergency Department and Medical Wards to support activity pressures, operational targets and to ensure safe staffing levels

Non Pay

- Non pay costs are £19.3m above budget, 7% excluding reserves. The reserves are a further of £24.1m off plan, reflecting the underlying deficit due to the lack of strategic transitional and CCG transformational funding.
- The key reasons for the non-pay overspend are:
 - Marginal costs associated with the volume increase in activity levels
 - Specific costs “pass through costs”, such as excluded drugs and devices and the use of the independent sector, which are supported via income
 - In year cost pressures across the CMGs and Corporate Directorates

3.4. The following chart highlights, graphically, the monthly trends of both income and expenditure to the year end.



	Apr £m	May £m	Jun £m	Jul £m	Aug £m	Sep £m	Oct £m	Nov £m	Dec £m	Jan £m	Feb £m	Mar £m	Total £m
Income	63.6	65.2	63.2	64.9	63.0	62.7	67.4	65.7	60.9	63.8	60.5	69.1	770.0
Costs	64.5	67.7	66.6	67.9	66.4	65.9	68.2	68.7	69.0	66.3	67.9	70.6	809.8
Deficit	(0.9)	(2.5)	(3.4)	(3.0)	(3.4)	(3.2)	(0.8)	(3.0)	(8.1)	(2.5)	(7.4)	(1.5)	(39.8)

3.5. The Trust has delivered the year end forecast deficit of £39.8m though there have been movements within the respective CMGs and Corporate Directorates from the month 7 agreed control total. This is shown in detail in Appendix 3, page 8.


3.6. A more detailed financial analysis of CMG and Corporate performance is provided through the Executive Performance Board financial report.

4. BALANCE SHEET

4.1. The effect of the Trust's financial position on its balance sheet is provided in the Appendices.

4.2. The retained earnings reserve will reduce by the Trust's £39.8m deficit. This is matched by the reduction of £19.5m cash and increase in Trade and Other Payables of £17.1m; as well as smaller movements on other current and non-current assets and liabilities.

4.3. The level of non-NHS debt has fluctuated across the year as shown in the following table:



4.4. The overall level of non-NHS debt at Month 12 was similar to the April 2013 position although the proportion of debt over 365 days has increased from £583k (8%) at the end of March 2013 to £908k (12%) in March 2014.

4.5. The Trust undertook a debt write-off exercise in March which reduced the level of outstanding aged debt. A total of 920 debts were written off at a total value of £835k. £79k was written off following advice from solicitors or debt collection agencies who instructed us that the debts were uneconomical to pursue. A further £633k was written off as our own credit control team had exhausted all credit control processes. £660k of the total write off related to overseas visitors debt. These debts were appropriately provided for in the Trust's bad debt provision. All debts to be written off were provided for in full in the Trust's bad debt provision and there will be no impact on the financial position as a result of these write-offs.

4.6. NHS debt is £19.9m at the end of Month 12. We would normally expect this debt to be around £7m however there are a number of additional year end balances including:

- several legacy debts totalling £2.6m carried forward from the demised PCTs and for which we are liaising with NHS England;
- £12m relating to the timing of performance related invoices.

5.7 We expect to collect these debts early in 2014-15.

5. CASH FLOW FORECAST

- 5.1. The Trust has achieved a cash balance of £0.5m at the year end, which is in line with its revised cash target. This target was reduced from £17.3m following a reset of the Trust's EFL by the NTDA, and reflects:
- capital cash payments of £29m for the full year;
 - a balance of outstanding and overdue creditor payments of £11m at the year-end; and
 - the receipt of £4.8m additional PDC in the year.
- 5.2. The Trust's cash flow forecast for the next 12 months is provided in the Appendices and shows that the Trust has received temporary borrowing in April of £15.5m, and plans to apply for further temporary borrowing to ensure an adequate level of cash in the first half of 2014/15 until permanent financing is secured.
- 5.3. Additionally, we have agreed with the LLR CCGs that they will continue to pay us £21m of SLA monies on the 1st of each month (instead of the 15th) from the 1st April 2014 which will enable us to better manage in month fluctuations in our cashflow.

6. CAPITAL

- 6.1. The capital position at the end of March is £36.7m against the revised annual plan, and equivalent CRL target, of £36.7m. The CRL was adjusted by £6m to reflect the underspend on the capital programme.
- 6.2. The Capital Group is continuing to work to develop a process to deliver an affordable and achievable Capital Plan for 2014/15 and beyond.

7. CONCLUSION

- 7.1. The Trust has not met its statutory break even duty and will receive an adverse VFM opinion on the Accounts.
- 7.2. The Trust had its EFL reset to enable the creditor backlog to be reduced in February 2014, and has delivered against this revised target
- 7.3. The CRL was also reduced by £6m to reflect the level of capital slippage, to give a year end CRL of £36.7m. This target has been delivered.

8. NEXT STEPS AND RECOMMENDATIONS

- 8.1. The Trust Board is **recommended** to:
- **Note** the contents of this report
 - **Confirm** the year end position, prior to the audited accounts, of a deficit of £39.8m.
 - **Note** the delivery of the EFL
 - **Note** the delivery against the CRL

Peter Hollinshead
Interim Director of Financial Strategy
11th April 2014

Income and Expenditure Account for the Period Ended 31 March 2014

	March 2014			April 2013 - March 2014		
	Plan £ 000	Actual £ 000	Variance (Adv) / Fav £ 000	Plan £ 000	Actual £ 000	Variance (Adv) / Fav £ 000
Elective	5,828	6,416	589	70,021	70,784	763
Day Case	4,132	4,363	231	49,448	51,182	1,734
Emergency	15,246	15,746	500	177,054	179,191	2,138
Outpatient	7,000	7,663	663	83,284	87,953	4,669
Non NHS Patient Care	613	1,330	717	7,267	6,365	(902)
Winter funding	0	1,982	1,982	0	9,839	9,839
Other	21,090	20,982	(107)	247,153	253,790	6,638
Patient Care Income	53,909	58,483	4,574	634,226	659,104	24,878
Teaching, R&D income	6,033	4,992	(1,041)	73,571	70,207	(3,364)
Other operating Income	3,124	5,621	2,497	38,185	40,691	2,506
Total Income	63,066	69,096	6,030	745,982	770,002	24,020
Pay Expenditure	37,102	41,124	(4,022)	447,612	474,163	(26,551)
Non Pay Expenditure	23,043	26,630	(3,587)	274,699	294,023	(19,324)
Central Reserves	(2,065)	0	(2,065)	(24,065)		(24,065)
Total Operating Expenditure	58,080	67,754	(9,674)	698,246	768,186	(69,940)
EBITDA	4,986	1,342	(3,644)	47,736	1,816	(45,920)
Interest Receivable	7	5	(2)	82	152	70
Interest Payable	(5)	(3)	2	(60)	(142)	(82)
Depreciation & Amortisation	(2,707)	(2,394)	313	(32,481)	(30,959)	1,522
Surplus / (Deficit) Before Dividend and Disposal of Fixed Assets	2,281	(1,050)	(3,331)	15,277	(29,133)	(44,410)
Dividend Payable on PDC	(964)	(386)	578	(11,568)	(10,660)	908
Net Surplus / (Deficit)	1,317	(1,436)	(2,753)	3,709	(39,793)	(43,502)
EBITDA MARGIN		1.94%			0.24%	

Patient Care Activity and Income – YTD Performance and Price / Volume Analysis

Case mix	Annual Plan (Activity)	Total YTD (Activity)	Variance YTD (Activity)	Variance YTD (Activity %)	Annual Plan (£000)	Total YTD (£000)	Variance YTD (£000)	Variance YTD (Activity %)
Day Case	80,497	84,674	4,177	5.19	49,448	51,182	1,734	3.51
Elective Inpatient	22,647	22,137	(511)	(2.25)	70,021	70,784	763	1.09
Emergency / Non-elective Inpatient	94,172	99,413	5,241	5.57	177,054	179,191	2,138	1.21
Marginal Rate Emergency Threshold (MRET)	0	0	0	0.00	(3,402)	(6,181)	(2,779)	81.70
Outpatient	733,651	767,038	33,387	4.55	83,284	87,953	4,669	5.61
Emergency Department	157,780	151,518	(6,261)	(3.97)	16,936	16,717	(219)	(1.29)
Winter Monies	0	0	0	0.00	0	9,839	9,839	
Other	7,731,446	8,020,915	289,469	3.74	233,619	243,216	9,597	4.11
Grand Total	8,820,192	9,145,695	325,503	3.69	626,959	652,700	25,741	4.11

Average tariff	Price Variance YTD %	Volume Variance YTD %	Price / Mix Variance (£000)	Volume Variance (£000)	Variance YTD (£000)
Day Case	(1.6)	5.2	(832)	2,566	1,734
Elective Inpatient	3.4	(2.3)	2,342	(1,578)	763
Emergency / Non-elective Inpatient	(4.1)	5.6	(7,716)	9,853	2,138
Marginal Rate Emergency Threshold (MRET)			(2,779)	0	(2,779)
Outpatient	1.0	4.6	879	3,790	4,669
Emergency Department	2.8	(4.0)	453	(672)	(219)
Winter Monies			0	9,839	9,839
Other			0	9,597	9,597
Grand Total	0.4	3.7	(7,653)	33,394	25,741

Draft YTD Position as at 31st March 2014

Division	CMG's	Income			Pay			Non Pay			TOTAL			M7 FOT	Better / (worse) than M7 FOT
		YTD	YTD	'Variance	YTD	YTD	'Variance	YTD	YTD	'Variance	YTD	YTD	'Variance	'Variance	
		Budget	YTD Actual	£000s	Budget	YTD Actual	£000s	Budget	YTD Actual	£000s	Budget	YTD Actual	£000s	£000s	
Clinical Cmg'S	C.H.U.G.S	120,465	124,193	3,727	45,500	46,784	(1,285)	35,817	40,933	(5,116)	39,148	36,475	(2,673)	(2,062)	(611)
	Clinical Support & Imaging	31,084	33,053	1,969	67,030	69,977	(2,947)	2,574	4,870	(2,296)	(38,519)	(41,795)	(3,275)	(3,395)	120
	Emergency & Specialist Med	105,808	120,098	14,289	63,868	75,012	(11,145)	30,011	32,478	(2,467)	11,930	12,608	678	(735)	1,412
	I.T.A.P.S	27,738	28,307	569	49,526	54,854	(5,329)	19,551	20,897	(1,346)	(41,339)	(47,444)	(6,105)	(3,472)	(2,633)
	Musculo & Specialist Surgery	96,134	97,043	909	43,571	45,546	(1,975)	18,415	20,517	(2,101)	34,148	30,981	(3,167)	(533)	(2,634)
	Renal, Respiratory & Cardiac	129,797	131,607	1,810	56,033	58,411	(2,378)	41,881	45,596	(3,715)	31,884	27,601	(4,283)	(4,242)	(41)
	Womens & Childrens	141,043	143,054	2,011	74,589	74,785	(195)	29,481	30,088	(607)	36,973	38,182	1,209	117	1,091
Clinical Cmg'S Total		652,070	677,355	25,285	400,116	425,369	(25,253)	177,730	195,379	(17,649)	74,225	56,608	(17,618)	(14,321)	(3,297)
Corporate	Communications & Ext Relations	33	29	(4)	755	846	(92)	121	150	(28)	(843)	(967)	(124)	(116)	(8)
	Corporate & Legal	0	72	72	971	960	11	1,168	1,256	(88)	(2,139)	(2,144)	(5)	(79)	73
	Corporate Medical	1,456	1,672	216	3,800	3,846	(46)	670	793	(122)	(3,014)	(2,966)	48	(94)	142
	Divisional Management Codes	625	127	(498)	3,941	3,747	194	677	291	386	(3,993)	(3,911)	82	967	(886)
	Facilities	11,684	11,974	290	1,274	1,213	61	54,874	52,142	2,732	(44,464)	(41,382)	3,082	922	2,160
	Finance & Procurement	50	83	33	4,351	4,293	58	2,690	2,246	444	(6,991)	(6,456)	535	74	461
	Human Resources	2,858	3,346	488	5,483	5,416	68	1,782	2,068	(287)	(4,407)	(4,138)	269	58	211
	Im&T	184	168	(16)	2,490	2,360	130	5,575	6,737	(1,161)	(7,882)	(8,929)	(1,047)	(218)	(829)
	Nursing	275	381	106	5,834	5,303	531	13,247	13,628	(380)	(18,806)	(18,550)	257	(80)	337
	Operations	278	1,232	954	2,934	3,292	(359)	214	654	(440)	(2,870)	(2,715)	156	(904)	1,059
	Strategic Devt	0	119	119	2,807	2,841	(35)	147	721	(574)	(2,953)	(3,443)	(489)	(927)	438
Corporate Total		17,443	19,203	1,760	34,640	34,118	521	81,166	80,685	481	(98,363)	(95,601)	2,762	(397)	3,160
Research & Development Total		27,939	27,528	(410)	12,857	12,932	(75)	15,083	14,340	742	(0)	256	257	191	66
Central Division Total		48,530	45,916	(2,614)	0	1,743	(1,743)	20,683	45,228	(24,545)	27,846	(1,056)	(28,902)	(28,975)	73
Grand Total		745,982	770,002	24,020	447,612	474,163	(26,551)	294,662	335,632	(40,970)	3,708	(39,793)	(43,501)	(43,503)	2

Balance Sheet

	Mar-13 £000's Actual	Apr-13 £000's Actual	May-13 £000's Actual	Jun-13 £000's Actual	Jul-13 £000's Actual	Aug-13 £000's Actual	Sep-13 £000's Actual	Oct-13 £000's Actual	Nov-13 £000's Actual	Dec-13 £000's Actual	Jan-14 £000's Actual	Feb-14 £000's Actual	Mar-14 £000's Forecast
Non Current Assets													
Property, plant and equipment	354,680	353,855	353,723	352,327	352,803	353,255	352,521	352,993	353,114	352,703	352,189	351,446	362,465
Intangible assets	5,318	5,160	5,012	4,940	4,795	4,650	4,627	4,419	4,273	4,328	4,179	4,030	8,020
Trade and other receivables	3,125	3,183	3,181	3,252	3,302	3,291	3,331	3,268	3,191	3,218	3,223	3,248	3,125
TOTAL NON CURRENT ASSETS	363,123	362,198	361,916	360,519	360,900	361,196	360,479	360,680	360,578	360,249	359,591	358,724	373,610
Current Assets													
Inventories	13,064	13,869	13,257	13,778	13,861	13,776	14,499	14,176	14,155	14,558	14,133	14,262	13,958
Trade and other receivables	44,616	42,408	42,628	35,756	40,713	44,182	46,674	42,210	49,634	50,922	50,734	45,458	49,061
Other Assets	40	40	40	40	40	40	40	40	40	40	40	40	0
Cash and cash equivalents	19,986	19,957	14,257	19,129	15,343	7,203	4,484	5,335	2,933	6,876	4,986	6,282	515
TOTAL CURRENT ASSETS	77,706	76,274	70,182	68,703	69,957	65,201	65,697	61,761	66,762	72,396	69,893	66,042	63,534
Current Liabilities													
Trade and other payables	(75,559)	(73,056)	(67,971)	(68,079)	(71,026)	(69,123)	(77,327)	(81,916)	(88,794)	(93,069)	(91,182)	(93,595)	(108,477)
Dividend payable	0	(964)	(1,928)	(2,892)	(3,856)	(4,820)	0	(964)	(1,928)	(2,892)	(3,856)	(4,820)	0
Borrowings	(2,726)	(2,800)	(2,800)	(2,800)	(2,800)	(2,800)	(2,800)	(2,800)	(2,800)	(2,727)	(2,800)	(2,800)	(6,590)
Provisions for liabilities and charges	(1,906)	(1,906)	(1,906)	(1,906)	(1,906)	(1,906)	(1,342)	(1,342)	(1,342)	(2,244)	(2,244)	(2,244)	(1,342)
TOTAL CURRENT LIABILITIES	(80,191)	(78,726)	(74,605)	(75,677)	(79,588)	(78,649)	(81,469)	(87,022)	(94,864)	(100,932)	(100,082)	(103,459)	(116,409)
NET CURRENT ASSETS (LIABILITIES)	(2,485)	(2,452)	(4,423)	(6,974)	(9,631)	(13,448)	(15,772)	(25,261)	(28,102)	(28,536)	(30,189)	(37,417)	(52,875)
TOTAL ASSETS LESS CURRENT LIABILITIES	360,638	359,746	357,493	353,545	351,269	347,748	344,707	335,419	332,476	331,713	329,402	321,307	320,735
Non Current Liabilities													
Borrowings	(10,906)	(10,958)	(11,190)	(10,809)	(11,522)	(11,484)	(11,159)	(10,797)	(10,410)	(10,887)	(11,103)	(8,910)	(5,890)
Other Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0
Provisions for liabilities and charges	(2,407)	(2,454)	(2,488)	(2,404)	(2,315)	(2,312)	(2,986)	(2,910)	(2,870)	(2,004)	(1,984)	(1,286)	(2,380)
TOTAL NON CURRENT LIABILITIES	(13,313)	(13,412)	(13,678)	(13,213)	(13,837)	(13,796)	(14,145)	(13,707)	(13,280)	(12,891)	(13,087)	(10,196)	(8,270)
TOTAL ASSETS EMPLOYED	347,325	346,334	343,815	340,332	337,432	333,952	330,562	321,712	319,196	318,822	316,315	311,111	312,465
Public dividend capital	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733	277,733	279,880	282,625
Revaluation reserve	64,628	64,626	64,628	64,632	64,632	64,628	64,628	64,628	64,628	64,628	64,628	64,628	64,619
Retained earnings	4,960	3,975	1,454	(2,033)	(4,933)	(8,409)	(11,799)	(20,649)	(23,165)	(23,539)	(26,046)	(33,397)	(34,779)
TOTAL TAXPAYERS EQUITY	347,325	346,334	343,815	340,332	337,432	333,952	330,562	321,712	319,196	318,822	316,315	311,111	312,465

Cashflow Statement and Forecast

Cash Flow Statement for the period ended 31 March 2014			
	2013/14	2013/14	2013/14
	Apr - Mar	Apr - Mar	Apr - Mar
	Plan	Actual	Variance
	£ 000	£ 000	£ 000
CASH FLOWS FROM OPERATING ACTIVITIES			
Operating surplus before Depreciation and Amortisation	48,185	1,816	(46,369)
Donated assets received credited to revenue and non cash	(300)	(765)	(465)
Interest paid	(845)	(458)	387
Movements in Working Capital:			
- Inventories (Inc)/Dec	-	(894)	(894)
- Trade and Other Receivables (Inc)/Dec	3,000	(2,770)	(5,770)
- Trade and Other Payables Inc/(Dec)	3,000	23,977	20,977
- Provisions Inc/(Dec)	(2,131)	(732)	1,399
PDC Dividends paid	(11,000)	(10,232)	768
Other non-cash movements		379	379
Net Cash Inflow / (Outflow) from Operating Activities	39,909	10,321	(29,588)
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest Received	96	66	(30)
Payments for Property, Plant and Equipment	(37,781)	(29,194)	8,587
Capital element of finance leases	(4,614)	(5,506)	(892)
Net Cash Inflow / (Outflow) from Investing Activities	(42,299)	(34,634)	7,665
CASH FLOWS FROM FINANCING ACTIVITIES			
New PDC	-	4,842	4,842
Other Capital Receipts	-	-	-
Net Cash Inflow / (Outflow) from Financing	-	4,842	4,842
Opening cash	19,713	19,986	273
Increase / (Decrease) in Cash	(2,390)	(19,471)	(17,081)
Closing cash	17,323	515	(16,808)

Cashflow 12 month forecast April 2014 to March 2015	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Cash Flows from Operating Activities												
Operating Surplus/(Deficit)	(3,393)	(2,652)	(2,465)	553	(2,138)	281	(43)	(4,256)	(3,718)	(2,578)	(6,369)	(1,991)
Depreciation and Amortisation	2,793	2,793	2,794	2,784	2,784	2,784	2,729	2,729	2,729	2,691	2,691	2,695
Impairments and Reversals	0	0	0	0	0	(1,445)	0	0	0	0	0	0
Interest Paid	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)
Dividend (Paid)/Refunded	0	0	0	0	0	(6,118)	0	0	0	0	0	(6,118)
(Increase)/Decrease in Trade and Other Receivables	(2,415)	(1,070)	83	(3,322)	2,898	(979)	(2,054)	3,929	(1,095)	(1,062)	4,070	(4,810)
(Increase)/Decrease in Other Current Assets	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200
Increase/(Decrease) in Trade and Other Payables	(9,237)	(4,762)	(1,131)	889	1,070	(7,885)	2,306	(535)	(212)	2,041	1,864	(3,845)
Provisions Utilised	(22)	(22)	(22)	(22)	(22)	(1,022)	(22)	(22)	(22)	(22)	(22)	(25)
Increase/(Decrease) in Movement in non Cash Provisions	607	958	907	1,060	888	880	1,156	814	871	713	889	889
Net Cash Inflow/(Outflow) from Operating Activities	(10,505)	(3,593)	1,328	3,104	6,642	(12,342)	5,234	3,821	(285)	2,945	4,285	(12,043)
CASH FLOWS FROM INVESTING ACTIVITIES												
Interest Received	8	8	8	8	8	8	8	8	8	8	8	8
(Payments) for Property, Plant and Equipment	(3,533)	(3,634)	(3,630)	(4,532)	(4,761)	(4,198)	(5,003)	(3,693)	(4,564)	(5,757)	(6,751)	(7,734)
Net Cash Inflow/(Outflow) from Investing Activities	(3,525)	(3,626)	(3,622)	(4,524)	(4,753)	(4,190)	(4,995)	(3,685)	(4,556)	(5,749)	(6,743)	(7,726)
NET CASH INFLOW/(OUTFLOW) BEFORE FINANCING	(14,030)	(7,219)	(2,294)	(1,420)	1,889	(16,532)	239	136	(4,841)	(2,804)	(2,458)	(19,769)
CASH FLOWS FROM FINANCING ACTIVITIES												
New Public Dividend Capital received in year: PDC Capital	0	0	0	0	0	8,000	0	0	0	0	0	16,557
New Public Dividend Capital received in year: PDC Revenue						37,500			6,000	3,000	4,000	2,943
Loans received from DH - Revenue Support Loans	15,500	8,000	3,000	2,000	0	0	0	0	0	0	0	0
Loans repaid to DH - Revenue Support Loans Repayment of Principal						(28,500)	0	0	0	0	0	0
Capital element of payments relating to PFI, LIFT Schemes and finance leases	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)
Net Cash Inflow/(Outflow) from Financing Activities	14,739	7,239	2,239	1,239	(761)	16,239	(761)	(761)	5,239	2,239	3,239	18,739
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	709	20	(55)	(181)	1,128	(293)	(522)	(625)	398	(565)	781	(1,030)
Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period	515	1,224	1,244	1,189	1,008	2,136	1,843	1,321	696	1,094	529	1,310
Cash and Cash Equivalents (and Bank Overdraft) at the end of the period	1,224	1,244	1,189	1,008	2,136	1,843	1,321	696	1,094	529	1,310	280

University Hospitals of Leicester NHS Trust
Capital Expenditure Report for the Period 1st April 2013 to 31st March 2014

	Project Director	Project Lead	Capital Plan 2013/14 £000's	YTD Spend 13/14 £000's	Expenditure Profile						Out Turn £000's	Variance £000's
					Actual							
					Qtr 1 £000's	Qtr 2 £000's	Qtr 3 £000's	Jan £000's	Feb £000's	Mar £000's		
Recurrent Budgets												
IM&T	John Adler	John Clarke	3,425	5,044	665	771	645	759	69	3,009	5,044	(3,019)
Medical Equipment	Kevin Harris	Paul Spier	5,197	5,129	491	651	1,499	275	179	1,007	5,129	59
Facilities Sub Group	Rachel Overfield	Andrew Challen	6,000	5,053	663	762	634	141	426	2,369	5,053	637
Discretionary Capital			381	355	234	36	79	14	6	6	355	15
M&E Installation Costs	Suzanne Khalid	Helen Bath	2,400	2,461	599	628	307	6	65	507	2,461	61
Total Recurrent Budgets			17,403	18,982	2,632	3,201	3,360	1,167	708	6,772	18,982	(2,466)
Reconfiguration Schemes												
Emergency Floor	Kate Shields	Jane Edyvean	3,100	3,102	164	297	621	12	210	1,069	3,102	39
Theatre Assessment Area (TAA)	Kate Shields	Ian Currie	1,080	1,069	41	609	494	104	17	919	1,069	(69)
Advanced Recovery LRI & LGH	Kate Shields	Ian Currie	514	527	112	12	31	7	35	330	527	(13)
OH Vascular Surgery	Kate Shields	Rachel Griffiths	650	194	0	0	69	(10)	7	194	194	155
Vascular Enabling	Kate Shields	Rachel Griffiths	300	30	0	0	0	2	4	30	30	104
Daycase / OPD Hub	Kate Shields	Nicky Topham	328	0	0	0	0	0	0	0	0	328
Ward 4 LGH / H Block Installation	Kate Shields	Nicky Topham	233	234	0	0	1	2	75	154	234	43
Modular Wards	Kate Shields	Louise Naylor	600	100	0	0	0	0	10	160	100	301
Brandon Unit Refurb: OPD 1-4	Kate Shields	Louise Naylor	100	65	0	10	68	(18)	0	0	65	10
ITU	Kate Shields	Richard Kinnearley	140	130	0	0	0	0	0	130	130	10
Popples Conversion	Kate Shields	Nigel Bond	300	327	0	0	28	0	27	272	327	(27)
Surgical Assessment Unit	Kate Shields	Debra Green	100	91	0	0	1	2	30	69	91	69
Endoscopy OH	Kate Shields	Capital Planning &	100	27	0	0	1	2	2	21	27	73
Feasibility Studies	Kate Shields	Capital Planning &	100	34	0	0	28	0	0	14	34	66
Total Reconfiguration			8,445	8,887	307	1,002	1,890	485	408	3,225	8,887	1,748
Corporate / Other Schemes												
Osborne Ventilation	Nick Moore	Michael Natbass	600	590	0	12	308	91	26	129	590	54
Endoscopy LRI	Nick Moore	Michael Natbass	165	169	79	69	17	0	2	4	169	7
Maternity Interim Development	Ian Soudamora	David Yeomanson	3,000	2,300	30	662	649	260	66	104	2,300	649
Aseptic Suite	Suzanne Khalid	Shar Patten	600	302	6	2	0	1	77	209	302	39
Diabetes BRU	Kevin Harris	Sue Enright	760	679	197	309	249	20	13	93	679	(129)
Respiratory BRU	Kevin Harris	Michelle Muesel	730	621	557	163	66	(3)	0	14	621	(91)
Stock Management System	Peter Hollins head	Andrea Smith	2,600	260	0	0	200	0	(3)	60	260	2,540
LIA Schemes	John Adler	Michelle Cloney	600	272	0	0	0	12	46	210	272	228
CMO Contingency	Peter Hollins head	Simon Sheppard	147	112	0	0	0	6	0	106	112	35
CHP Units	Rachel Overfield	Nigel Bond	2,147	1,809	0	0	16	(2)	171	1,722	1,809	241
Safer Hospitals Technology Fund	John Adler	John Clarke	2,350	0	0	0	0	0	0	0	0	2,350
Nursing Technology Fund	Rachel Overfield	Julia Ball	622	680	0	0	0	0	0	680	680	42
Improving Maternity Care Settings	Ian Soudamora	David Yeomanson	100	0	0	0	0	0	0	0	0	100
EDRM System	John Adler	John Clarke	1,639	1,079	0	490	236	(276)	0	691	1,079	660
Donations			300	765	64	61	165	29	0	465	765	(465)
Other Developments			729	720	192	36	213	94	47	109	720	0
			17,278	10,600	1,116	2,046	2,369	214	476	4,651	10,600	6,478
Total Capital Programme			43,217	37,469	3,855	6,401	7,342	1,866	1,644	16,547	37,469	5,769